|
1
|
Lima JV Júnior and Kater CE: The
pheochromocytoma/paraganglioma syndrome: An overview on mechanisms,
diagnosis and management. Int Braz J Urol. 49:307–319.
2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Al Subhi AR, Boyle V and Elston MS:
Systematic review: Incidence of pheochromocytoma and paraganglioma
over 70 years. J Endocr Soc. 6(bvac105)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lam AK: Update on adrenal tumours in 2017
world health organization (WHO) of endocrine tumours. Endocr
Pathol. 28:213–227. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pourian M, Mostafazadeh DB and Soltani A:
Does this patient have pheochromocytoma? A systematic review of
clinical signs and symptoms. J Diabetes Metab Disord.
15(11)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sherwani P, Anand R, Narula MK, Siddiqui
AA and Aggarwal S: Concurrent nonfunctional paraganglioma of the
retroperitoneum and urinary bladder: A case report with literature
review. Indian J Radiol Imaging. 25:198–201. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Renard J, Clerici T, Licker M and Triponez
F: Pheochromocytoma and abdominal paraganglioma. J Visc Surg.
148:e409–e416. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
McNicol AM: Update on tumours of the
adrenal cortex, phaeochromocytoma and extra-adrenal paraganglioma.
Histopathology. 58:155–168. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Berends AMA, Buitenwerf E, de Krijger RR,
Veeger NJGM, van der Horst-Schrivers ANA, Links TP and Kerstens MN:
Incidence of pheochromocytoma and sympathetic paraganglioma in the
Netherlands: A nationwide study and systematic review. Eur J Intern
Med. 51:68–73. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lenders JWM, Kerstens MN, Amar L, Prejbisz
A, Robledo M, Taieb D, Pacak K, Crona J, Zelinka T, Mannelli M, et
al: Genetics, diagnosis, management and future directions of
research of phaeochromocytoma and paraganglioma: A position
statement and consensus of the working group on endocrine
hypertension of the european society of hypertension. J Hypertens.
38:1443–1456. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kinney MA, Warner ME, vanHeerden JA,
Horlocker TT, Young WF Jr, Schroeder DR, Maxson PM and Warner MA:
Perianesthetic risks and outcomes of pheochromocytoma and
paraganglioma resection. Anesth Analg. 91:1118–1123.
2000.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cui Y, Ma X, Gao Y, Chang X, Chen S, Lu L
and Tong A: Local-regional recurrence of
pheochromocytoma/paraganglioma: Characteristics, risk factors and
outcomes. Front Endocrinol (Lausanne). 12(762548)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Holscher I, van den Berg TJ, Dreijerink
KMA, Engelsman AF and Nieveen van Dijkum EJM: Recurrence rate of
sporadic pheochromocytomas after curative adrenalectomy: A
systematic review and meta-analysis. J Clin Endocrinol Metab.
106:588–597. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Plouin PF, Amar L, Dekkers OM, Fassnacht
M, Gimenez-Roqueplo AP, Lenders JW, Lussey-Lepoutre C and Steichen
O: Guideline Working Group. European society of endocrinology
clinical practice guideline for long-term follow-up of patients
operated on for a phaeochromocytoma or a paraganglioma. Eur J
Endocrinol. 174:G1–G10. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ayala-Ramirez M, Feng L, Johnson MM, Ejaz
S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, et al:
Clinical risk factors for malignancy and overall survival in
patients with pheochromocytomas and sympathetic paragangliomas:
primary tumor size and primary tumor location as prognostic
indicators. J Clin Endocrinol Metab. 96:717–725. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Whalen RK, Althausen AF and Daniels GH:
Extra-adrenal pheochromocytoma. J Urol. 147:1–10. 1992.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chinese Society of Endocrinology: Expert
consensus on the diagnosis and treatment of pheochromocytoma and
paraganglioma. Chin J Endocrinol Metab. 36:737–750. 2020.
|
|
17
|
Fagundes GFC and Almeida MQ: Perioperative
management of pheochromocytomas and sympathetic paragangliomas. J
Endocr Soc. 6(bvac004)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Olson JR and Abell MR: Nonfunctional,
nonchromaffin paragangliomas of the retroperitoneum. Cancer.
23:1358–1367. 1969.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lack EE, Cubilla AL, Woodruff JM and
Lieberman PH: Extra-adrenal paragangliomas of the retroperitoneum:
A clinicopathologic study of 12 tumors. Am J Surg Pathol.
4:109–120. 1980.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nishino M, Hayakawa K, Minami M, Yamamoto
A, Ueda H and Takasu K: Primary retroperitoneal neoplasms: CT and
MR imaging findings with anatomic and pathologic diagnostic clues.
Radiographics. 23:45–57. 2003.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Vernuccio F, Taibbi A, Picone D, LA Grutta
L, Midiri M, Lagalla R, Lo Re G and Bartolotta TV: Imaging of
gastrointestinal stromal tumors: From diagnosis to evaluation of
therapeutic response. Anticancer Res. 36:2639–2648. 2016.PubMed/NCBI
|
|
22
|
Leung K, Stamm M, Raja A and Low G:
Pheochromocytoma: the range of appearances on ultrasound, CT, MRI,
and functional imaging. AJR Am J Roentgenol. 200:370–378.
2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Taïeb D, Timmers HJ, Hindié E, Guillet BA,
Neumann HP, Walz MK, Opocher G, de Herder WW, Boedeker CC, de
Krijger RR, et al: EANM 2012 guidelines for radionuclide imaging of
phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging.
39:1977–1995. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fiebrich HB, Brouwers AH, Kerstens MN,
Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van
der Wal JE, et al: 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron
emission tomography is superior to conventional imaging with
(123)I-metaiodobenzylguanidine scintigraphy, computer tomography,
and magnetic resonance imaging in localizing tumors causing
catecholamine excess. J Clin Endocrinol Metab. 94:3922–3930.
2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wiseman GA, Pacak K, O'Dorisio MS, Neumann
DR, Waxman AD, Mankoff DA, Heiba SI, Serafini AN, Tumeh SS,
Khutoryansky N and Jacobson AF: Usefulness of 123I-MIBG
scintigraphy in the evaluation of patients with known or suspected
primary or metastatic pheochromocytoma or paraganglioma: results
from a prospective multicenter trial. J Nucl Med. 50:1448–1454.
2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Timmers HJ, Chen CC, Carrasquillo JA,
Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams
KT and Pacak K: Staging and functional characterization of
pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose
(18F-FDG) positron emission tomography. J Natl Cancer Inst.
104:700–708. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Janssen I, Blanchet EM, Adams K, Chen CC,
Millo CM, Herscovitch P, Taieb D, Kebebew E, Lehnert H, Fojo AT and
Pacak K: Superiority of [68Ga]-DOTATATE PET/CT to other functional
imaging modalities in the localization of SDHB-associated
metastatic pheochromocytoma and paraganglioma. Clin Cancer Res.
21:3888–3895. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Garcia-Carbonero R, Matute Teresa F,
Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I,
Alvarez-Escola C, Arístegui M, Bella-Cueto MR, Ferrer-Albiach C and
Hanzu FA: Multidisciplinary practice guidelines for the diagnosis,
genetic counseling and treatment of pheochromocytomas and
paragangliomas. Clin Transl Oncol. 23:1995–2019. 2021.PubMed/NCBI View Article : Google Scholar
|
